Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial
OncologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- JAMA oncology
- Publicado em
- 1 abr 2020
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial
Fausto Petrelli, Roberto Labianca, Alberto Zaniboni, Sara Lonardi, Fabio Galli, Eliana Rulli, Gerardo Rosati, Salvatore Corallo, Monica Ronzoni, Giovanni Gerardo Cardellino et al.
Descritores MeSH
- Neoplasm Recurrence, Local
- Colorectal Neoplasms
- Chemotherapy, Adjuvant
- Antineoplastic Combined Chemotherapy Protocols
- Child
- Child, Preschool
- Leucovorin
- Female
- Fluorouracil
- Humans
Veja também
Estudos relacionados
- Neoadjuvant Chemotherapy With Oxaliplatin and Fluoropyrimidine Versus Upfront Surgery for Locally Advanced Colon Cancer: The Randomized, Phase III OPTICAL Trial
- Preoperative Treatment of Locally Advanced Rectal Cancer
- Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial
- Perioperative systemic therapy versus surgery alone for resectable colorectal peritoneal-only metastases (CAIRO6): a randomised, open-label, phase 3 trial